Literature DB >> 18320564

RNA interference: an emerging generation of biologicals.

Neeta Shrivastava1, Anshu Srivastava.   

Abstract

RNA interference (RNAi) is a mechanism displayed by most eukaryotic cells to rid themselves of foreign double-stranded RNA molecules. RNAi has now been demonstrated to function in mammalian cells to alter gene expression, and has been used as a means for genetic discovery as well as a possible strategy for genetic correction. RNAi was first described in animal cells by Fire and colleagues in the nematode, Caenorhabditis elegans. Knowledge of RNAi mechanism in mammalian cell in 2001 brought a storm in the field of drug discovery. During the past few years scientists all over the world are focusing on exploiting the therapeutic potential of RNAi for identifying a new class of therapeutics. The applications of RNAi in medicine are unlimited because all cells possess RNAi machinery and hence all genes can be potential targets for therapy. RNAi can be developed as an endogenous host defense mechanism against many infections and diseases. Several studies have demonstrated therapeutic benefits of small interfering RNAs and micro RNAs in animal models. This has led to the rapid advancement of the technique from research discovery to clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18320564      PMCID: PMC7161898          DOI: 10.1002/biot.200700215

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  124 in total

1.  RNA interference is mediated by 21- and 22-nucleotide RNAs.

Authors:  S M Elbashir; W Lendeckel; T Tuschl
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

2.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.

Authors:  S M Hammond; E Bernstein; D Beach; G J Hannon
Journal:  Nature       Date:  2000-03-16       Impact factor: 49.962

3.  bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila.

Authors:  Julius Brennecke; David R Hipfner; Alexander Stark; Robert B Russell; Stephen M Cohen
Journal:  Cell       Date:  2003-04-04       Impact factor: 41.582

Review 4.  Revealing the world of RNA interference.

Authors:  Craig C Mello; Darryl Conte
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

5.  RNAi-induced gene silencing by local electroporation in targeting brain region.

Authors:  Yukio Akaneya; Bin Jiang; Tadaharu Tsumoto
Journal:  J Neurophysiol       Date:  2005-01       Impact factor: 2.714

Review 6.  RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.

Authors:  Mingjie Li; Haitang Li; John J Rossi
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

7.  Role for a bidentate ribonuclease in the initiation step of RNA interference.

Authors:  E Bernstein; A A Caudy; S M Hammond; G J Hannon
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

8.  Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart.

Authors:  Sei Tsunoda; Osam Mazda; Yohei Oda; Yasunori Iida; Satoshi Akabame; Tsunao Kishida; Masaharu Shin-Ya; Hidetsugu Asada; Satoshi Gojo; Jiro Imanishi; Hiroaki Matsubara; Toshikazu Yoshikawa
Journal:  Biochem Biophys Res Commun       Date:  2005-10-14       Impact factor: 3.575

9.  Small interfering RNA inhibits hepatitis B virus replication in mice.

Authors:  Hilla Giladi; Mali Ketzinel-Gilad; Ludmila Rivkin; Yaakov Felig; Ofer Nussbaum; Eithan Galun
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

10.  In vivo activity of nuclease-resistant siRNAs.

Authors:  Juliana M Layzer; Anton P McCaffrey; Alice K Tanner; Zan Huang; Mark A Kay; Bruce A Sullenger
Journal:  RNA       Date:  2004-05       Impact factor: 4.942

View more
  15 in total

1.  Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.

Authors:  Adrian G Rosas-Taraco; David M Higgins; Joaquín Sánchez-Campillo; Eric J Lee; Ian M Orme; Mercedes González-Juarrero
Journal:  Tuberculosis (Edinb)       Date:  2010-12-31       Impact factor: 3.131

2.  Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.

Authors:  Kerry P Mahon; Kevin T Love; Kathryn A Whitehead; June Qin; Akin Akinc; Elizaveta Leshchiner; Ignaty Leshchiner; Robert Langer; Daniel G Anderson
Journal:  Bioconjug Chem       Date:  2010-08-18       Impact factor: 4.774

3.  New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Authors:  Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

4.  The effects of p38 gene silencing on breast cancer cells.

Authors:  Fulya Doğaner; Didem Turgut Coşan; Hasan Veysi Güneş; Irfan Değirmenci; Cengiz Bal
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

5.  Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis.

Authors:  Adrian G Rosas-Taraco; David M Higgins; Joaquín Sánchez-Campillo; Eric J Lee; Ian M Orme; Mercedes González-Juarrero
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-18       Impact factor: 6.914

6.  Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells.

Authors:  Song-Tao Xu; Xiang Ding; Qing-Feng Ni; Shao-Ju Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

7.  Optochemical control of deoxyoligonucleotide function via a nucleobase-caging approach.

Authors:  Qingyang Liu; Alexander Deiters
Journal:  Acc Chem Res       Date:  2013-08-28       Impact factor: 22.384

Review 8.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

9.  siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells.

Authors:  Fatemeh Bagheri; Shahrokh Safarian; Mohamadreza Baghaban Eslaminejad; Nader Sheibani
Journal:  Cell Oncol (Dordr)       Date:  2013-11-26       Impact factor: 6.730

10.  Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir.

Authors:  Solenne Vigne; Sophie Duraffour; Graciela Andrei; Robert Snoeck; Daniel Garin; Jean-Marc Crance
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.